236 related articles for article (PubMed ID: 10438356)
1. Quantitative effects of valacyclovir on the replication of cytomegalovirus (CMV) in persons with advanced human immunodeficiency virus disease: baseline CMV load dictates time to disease and survival. The AIDS Clinical Trials Group 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.
Emery VC; Sabin C; Feinberg JE; Grywacz M; Knight S; Griffiths PD
J Infect Dis; 1999 Sep; 180(3):695-701. PubMed ID: 10438356
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus (CMV) polymerase chain reaction profiles in individuals with advanced human immunodeficiency virus infection: relationship to CMV disease.
Nokta MA; Holland F; De Gruttola V; Emery VC; Jacobson MA; Griffiths P; Pollard RB; Feinberg JE;
J Infect Dis; 2002 Jun; 185(12):1717-22. PubMed ID: 12085316
[TBL] [Abstract][Full Text] [Related]
3. The effect of valaciclovir on cytomegalovirus viremia and viruria detected by polymerase chain reaction in patients with advanced human immunodeficiency virus disease. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.
Griffiths PD; Feinberg JE; Fry J; Sabin C; Dix L; Gor D; Ansari A; Emery VC
J Infect Dis; 1998 Jan; 177(1):57-64. PubMed ID: 9419170
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.
Feinberg JE; Hurwitz S; Cooper D; Sattler FR; MacGregor RR; Powderly W; Holland GN; Griffiths PD; Pollard RB; Youle M; Gill MJ; Holland FJ; Power ME; Owens S; Coakley D; Fry J; Jacobson MA
J Infect Dis; 1998 Jan; 177(1):48-56. PubMed ID: 9419169
[TBL] [Abstract][Full Text] [Related]
5. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
Lowance D; Neumayer HH; Legendre CM; Squifflet JP; Kovarik J; Brennan PJ; Norman D; Mendez R; Keating MR; Coggon GL; Crisp A; Lee IC
N Engl J Med; 1999 May; 340(19):1462-70. PubMed ID: 10320384
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360).
Erice A; Tierney C; Hirsch M; Caliendo AM; Weinberg A; Kendall MA; Polsky B;
Clin Infect Dis; 2003 Aug; 37(4):567-78. PubMed ID: 12905142
[TBL] [Abstract][Full Text] [Related]
7. Valacyclovir provides optimum acyclovir exposure for prevention of cytomegalovirus and related outcomes after organ transplantation.
Fiddian P; Sabin CA; Griffiths PD
J Infect Dis; 2002 Oct; 186 Suppl 1():S110-5. PubMed ID: 12353195
[TBL] [Abstract][Full Text] [Related]
8. The economic value of valacyclovir prophylaxis in transplantation.
Squifflet JP; Legendre C
J Infect Dis; 2002 Oct; 186 Suppl 1():S116-22. PubMed ID: 12353196
[TBL] [Abstract][Full Text] [Related]
9. Effect of a 14-day course of foscarnet on cytomegalovirus (CMV) blood markers in a randomized study of human immunodeficiency virus-infected patients with persistent CMV viremia. Agence National de Recherche du SIDA 023 Study Group.
Salmon-Céron D; Fillet AM; Aboulker JP; Gérard L; Houhou N; Carrière I; Ostinelli J; Vildé JL; Brun-Vézinet F; Leport C
Clin Infect Dis; 1999 Apr; 28(4):901-5. PubMed ID: 10825058
[TBL] [Abstract][Full Text] [Related]
10. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
[TBL] [Abstract][Full Text] [Related]
11. Expression of the late cytomegalovirus (CMV) pp150 transcript in leukocytes of AIDS patients is associated with a high viral DNA load in leukocytes and presence of CMV DNA in plasma.
Boivin G; Handfield J; Toma E; Lalonde R; Bergeron MG
J Infect Dis; 1999 May; 179(5):1101-7. PubMed ID: 10191210
[TBL] [Abstract][Full Text] [Related]
12. Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy.
O'Sullivan CE; Drew WL; McMullen DJ; Miner R; Lee JY; Kaslow RA; Lazar JG; Saag MS
J Infect Dis; 1999 Sep; 180(3):847-9. PubMed ID: 10438377
[TBL] [Abstract][Full Text] [Related]
13. The status of CMV viral load testing.
Feinberg J
AIDS Clin Care; 1996 Oct; 8(10):81. PubMed ID: 11363986
[TBL] [Abstract][Full Text] [Related]
14. Response of asymptomatic cytomegalovirus viraemia to oral ganciclovir 3 g/day or 6 g/day in HIV-infected patients.
Grzywacz M; Deayton JR; Bowen EF; Wilson P; Emery VC; Johnson MA; Griffiths PD
J Med Virol; 1999 Nov; 59(3):323-8. PubMed ID: 10502264
[TBL] [Abstract][Full Text] [Related]
15. Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis.
Vusirikala M; Wolff SN; Stein RS; Brandt SJ; Morgan DS; Greer JP; Schuening FG; Dummer JS; Goodman SA
Bone Marrow Transplant; 2001 Aug; 28(3):265-70. PubMed ID: 11535994
[TBL] [Abstract][Full Text] [Related]
16. Use of polymerase chain reaction to provide prognostic information on human cytomegalovirus disease after liver transplantation.
Lao WC; Lee D; Burroughs AK; Lanzani G; Rolles K; Emery VC; Griffiths PD
J Med Virol; 1997 Mar; 51(3):152-8. PubMed ID: 9139077
[TBL] [Abstract][Full Text] [Related]
17. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial.
Zuckerman RA; Lucchetti A; Whittington WL; Sanchez J; Coombs RW; Zuñiga R; Magaret AS; Wald A; Corey L; Celum C
J Infect Dis; 2007 Nov; 196(10):1500-8. PubMed ID: 18008230
[TBL] [Abstract][Full Text] [Related]
18. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection.
Reischig T; Jindra P; Svecová M; Kormunda S; Opatrný K; Treska V
J Clin Virol; 2006 Jun; 36(2):146-51. PubMed ID: 16531113
[TBL] [Abstract][Full Text] [Related]
19. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation.
Winston DJ; Yeager AM; Chandrasekar PH; Snydman DR; Petersen FB; Territo MC;
Clin Infect Dis; 2003 Mar; 36(6):749-58. PubMed ID: 12627359
[TBL] [Abstract][Full Text] [Related]
20. [The prognostic value of cytomegalovirus antigenemia and viremia for the development of cytomegalovirus disease and the survival of AIDS patients].
Cartón JA; Maradona JA; de Oña M; Asensi V; Melón S; García-Alcalde ML; Rodríguez-Junquera M; Moreno-Torrico A; de Zárraga M
Med Clin (Barc); 1999 Sep; 113(6):205-9. PubMed ID: 10472608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
